Bayer stärkt seine Position im Markt für pulmonale arteriell Hypertonie
Bayer’s engagement in the pulmonary arterial hypertension (PAH) market is decisively highlighted by the approval of ADEMPAS, a riociguat‑based therapy jointly developed with Merck. The drug targets the NO/cGMP signaling pathway and represents a broader shift towards newer mechanisms of action in PAH treatment.
Market analysts emphasize that Bayer’s pipeline remains robust, with emerging agents such as ralipag and various treprostinil formulations poised to expand therapeutic options. The company’s ongoing participation in regulatory discussions and clinical development initiatives aims to address unmet needs within the PAH therapeutic landscape.
These developments underscore Bayer’s strategic commitment to delivering innovative solutions for PAH patients, positioning the company as a key player in shaping the future of pulmonary vascular medicine.
